KSC · 003000.KS
Bukwang Pharmaceutical Co., Ltd.
₩3,670-₩30 (-0.81%)
Bukwang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 62.89% below the high.
Loading market information…
KOE · 256840.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
BNC Korea Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BNC Korea Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in South Korea, BNC Korea Co., Ltd. focuses on the research, development, manufacturing, and distribution of various biomaterials. The company's diverse product range features hyaluronic acid (HA) and skin booster fillers, including brand names like Cutegel, Cutegel Lidocaine, FLORE Lidocaine, ChungA-an, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, all designed for the temporary reduction of facial wrinkles through physical restoration. Beyond aesthetic products, BNC Korea also manufactures Hibarry, a specialized dressing for deep-cavity wounds, which helps mitigate spinal cord adhesion during surgery. Another key medical product is GENTA Q, a white collagen sponge created to protect wounds by preventing contamination. Additionally, the company offers a line of beauty solutions, encompassing face mask gels, mild cleansing foams, and brightening peeling gels. With a significant international presence, BNC Korea exports its products to 45 countries. The firm was founded in 2007 and is headquartered in Daegu, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩3,670-₩30 (-0.81%)
Bukwang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 62.89% below the high.
₩33,850-₩150 (-0.44%)
Dong-A ST Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.82% below the high.
₩16,910+₩60 (+0.36%)
Korea United Pharm Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.43% below the high.
₩6,930-₩550 (-7.35%)
FutureChem Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 75.22% below the high.
₩16,960-₩70 (-0.41%)
Huons Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 59.13% below the high.
₩17,570-₩410 (-2.28%)
Suheung Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.95% below the high.
₩8,680+₩980 (+12.73%)
Daewon Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.5% below the high.
₩8,400-₩160 (-1.87%)
Boditech Med Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.64% below the high.
